Nitro-L-arginine	nitro-l-arginine	O	O	O	O
methyl	methyl	O	O	O	O
ester	ester	O	O	O	O
:	:	O	O	O	O
a	a	O	O	O	O
potential	potential	O	O	O	O
protector	protector	O	O	O	O
against	against	O	O	O	O
gentamicin	gentamicin	CHEMICALS	O	OTHERS	I
ototoxicity	ototoxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
nitric	nitric	CHEMICALS	O	OTHERS	I
oxide	oxide	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
NO	no	O	O	O	O
)	)	O	O	O	O
inhibitor	inhibitor	O	O	O	O
nitro-L-arginine	nitro-l-arginine	O	O	O	O
methyl	methyl	O	O	O	O
ester	ester	O	O	O	O
(	(	O	O	O	O
L-NAME	l-name	O	O	O	O
)	)	O	O	O	O
may	may	O	O	O	O
act	act	O	O	O	O
as	as	O	O	O	O
an	an	O	O	O	O
otoprotectant	otoprotectant	O	O	O	O
against	against	O	O	O	O
high-frequency	high-frequency	O	O	O	O
hearing	hearing	O	DISEASE	OTHERS	I
loss	loss	O	DISEASE	OTHERS	I
caused	caused	O	O	O	O
by	by	O	O	O	O
gentamicin	gentamicin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
but	but	O	O	O	O
further	further	O	O	O	O
studies	studies	O	O	O	O
are	are	O	O	O	O
needed	needed	O	O	O	O
to	to	O	O	O	O
confirm	confirm	O	O	O	O
this	this	O	O	O	O
.	.	O	O	O	O

Aminoglycoside	aminoglycoside	CHEMICALS	O	OTHERS	I
antibiotics	antibiotics	O	O	O	O
are	are	O	O	O	O
still	still	O	O	O	O
widely	widely	O	O	O	O
used	used	O	O	O	O
by	by	O	O	O	O
virtue	virtue	O	O	O	O
of	of	O	O	O	O
their	their	O	O	O	O
efficacy	efficacy	O	O	O	O
and	and	O	O	O	O
low	low	O	O	O	O
cost	cost	O	O	O	O
.	.	O	O	O	O

Their	their	O	O	O	O
ototoxicity	ototoxicity	O	DISEASE	OTHERS	I
is	is	O	O	O	O
a	a	O	O	O	O
serious	serious	O	O	O	O
health	health	O	O	O	O
problem	problem	O	O	O	O
and	and	O	O	O	O
,	,	O	O	O	O
as	as	O	O	O	O
their	their	O	O	O	O
ototoxic	ototoxic	O	O	OTHERS	I
mechanism	mechanism	O	O	O	O
involves	involves	O	O	O	O
the	the	O	O	O	O
production	production	O	O	O	O
of	of	O	O	O	O
NO	no	O	O	O	O
,	,	O	O	O	O
we	we	O	O	O	O
need	need	O	O	O	O
to	to	O	O	O	O
assess	assess	O	O	O	O
the	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
NO	no	O	O	O	O
inhibitors	inhibitors	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
prevention	prevention	O	O	O	O
of	of	O	O	O	O
aminoglycoside-induced	aminoglycoside-induced	O	O	O	O
sensorineural	sensorineural	O	DISEASE	OTHERS	I
hearing	hearing	O	DISEASE	OTHERS	I
loss	loss	O	DISEASE	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
this	this	O	O	O	O
experimental	experimental	O	O	O	O
study	study	O	O	O	O
we	we	O	O	O	O
used	used	O	O	O	O
30	30	O	O	O	O
Sprague-Dawley	sprague-dawley	O	O	O	O
rats	rats	O	O	O	O
,	,	O	O	O	O
27	27	O	O	O	O
of	of	O	O	O	O
which	which	O	O	O	O
had	had	O	O	O	O
gentamicin	gentamicin	CHEMICALS	O	OTHERS	I
instilled	instilled	O	O	O	O
into	into	O	O	O	O
the	the	O	O	O	O
middle	middle	O	O	O	O
ear	ear	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
otoprotectant	otoprotectant	O	O	O	O
L-NAME	l-name	O	O	O	O
was	was	O	O	O	O
administered	administered	O	O	O	O
topically	topically	O	O	O	O
to	to	O	O	O	O
12/27	12/27	O	O	O	O
animals	animals	O	O	O	O
.	.	O	O	O	O

Its	its	O	O	O	O
effect	effect	O	O	O	O
was	was	O	O	O	O
determined	determined	O	O	O	O
in	in	O	O	O	O
terms	terms	O	O	O	O
of	of	O	O	O	O
attenuation	attenuation	O	O	O	O
of	of	O	O	O	O
hearing	hearing	O	DISEASE	OTHERS	I
loss	loss	O	DISEASE	OTHERS	I
,	,	O	O	O	O
measured	measured	O	O	O	O
by	by	O	O	O	O
shifts	shifts	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
auditory	auditory	O	O	O	O
brainstem	brainstem	O	O	O	O
response	response	O	O	O	O
threshold	threshold	O	O	O	O
.	.	O	O	O	O

L-NAME	l-name	O	O	O	O
reduced	reduced	O	O	O	O
gentamicin-induced	gentamicin-induced	O	O	O	O
hearing	hearing	O	DISEASE	OTHERS	I
loss	loss	O	DISEASE	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
high-frequency	high-frequency	O	O	O	O
range	range	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
gave	gave	O	O	O	O
no	no	O	O	O	O
protection	protection	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
middle	middle	O	O	O	O
or	or	O	O	O	O
low	low	O	O	O	O
frequencies	frequencies	O	O	O	O
.	.	O	O	O	O

